Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Forecast
CRBP analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.90 / 5 from 10 analysts
- Price target
- $34.02 average of analyst targets
- Upside to target
- +652.8% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-1.45
- 52-week range
- $4.33 – $19.36
CRBP analyst ratings
10 analystsNumber of analysts at each rating.
CRBP price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CRBP earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.21 | −$1.91 | −$0.73 | −$1.90 | +36.1% | 10 |
| Current fiscal year (2026) | −$5.43 | −$6.81 | −$4.06 | −$5.90 | +7.9% | 10 |
| Next fiscal year (2027) | −$5.51 | −$6.90 | −$2.97 | −$5.43 | −1.5% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CRBP revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.1M | $0 | $10.0M | 0.0% | 9 |
| Current fiscal year (2026) | $1.1M | $0 | $10.0M | 0.0% | 9 |
| Next fiscal year (2027) | $2.4M | $0 | $20.0M | +116.0% | 9 |
CRBP EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CRBP revenue: reported and forecast
CRBP EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.03 | −$1.03 | −$1.21 | −$1.21 | −$1.21 | +17.4% | 2 up · 7 down |
| Current fiscal year (2026) | −$4.57 | −$4.57 | −$5.43 | −$5.43 | −$5.43 | +19.0% | 0 up · 9 down |
| Next fiscal year (2027) | −$5.07 | −$5.08 | −$5.51 | −$5.51 | −$5.51 | +8.7% | 4 up · 5 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CRBP earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CRBP beat in 5 of 12.
What analysts expect from CRBP
10 analysts cover Corbus Pharmaceuticals; their consensus rating is strong buy (4.90 on a 1–5 scale, where 5 is a strong buy). The average price target is $34.02, 652.8% above the latest close of $4.52. Analysts expect earnings of −$5.43 per share for 2026, +7.9% from a year earlier. For 2027 the average estimate is −$5.51 per share on revenue of $2.4 million. Corbus Pharmaceuticals beat the EPS estimate in 5 of the last 12 quarters.
Related: CRBP income statement, CRBP key metrics, CRBP chart. See the CRBP stock overview for the latest quote and news.
CRBP forecast FAQ
What is Corbus Pharmaceuticals's price target?
The average analyst price target for Corbus Pharmaceuticals is $34.02, 652.8% above the latest close of $4.52.
Is Corbus Pharmaceuticals a buy, hold or sell?
Of 10 analysts covering Corbus Pharmaceuticals, 9 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Corbus Pharmaceuticals's EPS forecast?
Analysts forecast −$5.43 per share for 2026 (range −$6.81 to −$4.06); for 2027 the estimate is −$5.51.
What is Corbus Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $1.1 million, growth of 0.0%; for 2027 it is $2.4 million.
When does Corbus Pharmaceuticals report earnings?
Corbus Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-1.45.
Does Corbus Pharmaceuticals usually beat earnings estimates?
Corbus Pharmaceuticals reported EPS at or above the analyst estimate in 5 of the last 12 quarters.